

1 **Title Page**

2 **Full title:** An After-Action Review of COVID-19 Cases and Mitigation Measures at US

3 Mission India, March 2020-July 2021

4

5 **Short title:** COVID-19 Cases and Mitigation Measures at US Mission India

6

7 **Authors:** Jaspreet Singh¹, Rajesh Yadav², Samantha Robinson¹, Mark Vanelli¹, Melissa

8 Nyendak², Meghna Desai²

9

10 **Author affiliations**

11 1. Health Unit, US Embassy, New Delhi, India

12 2. US Centers for Disease Control and Prevention, New Delhi, India

13

14 **Corresponding Author details:** Dr. Jaspreet Singh, Health Unit, US Embassy, New Delhi

15 Email – dr.singh.jaspreet@outlook.com

16

17 **Author contribution:** Each author contributed equally to conceptualizing, data analysis,

18 writing and reviewing the manuscript.

19

20 **Competing interests:** Nil

21

22 **Abstract**

23 **Introduction:** Between March 2020-June 2021, over 30 million COVID-19 cases were
24 reported in India. We assessed the COVID-19 response across the US Mission India (US
25 Embassy New Delhi, US Consulates – Mumbai, Hyderabad, Chennai and Kolkata) to plan future
26 mitigation efforts and fill gaps in knowledge about COVID-19 transmission in a unique
27 community like the US Mission.

28 **Method:** We described COVID-19 mitigation activities undertaken by the five US Mission
29 India posts and conducted a secondary analysis of case investigation and contact tracing program
30 data collected by the Health Unit from March 2020–July 2021.

31 **Results:** US Mission in India, in collaboration with multiple internal agencies, initiated
32 COVID-19 mitigation activities in March 2020. Activities included educational sessions, training
33 for infection prevention and control, health and safety assessments, and the development of
34 standard operating procedures (SOPs). The Health Unit and US CDC India office initiated
35 COVID-19 case investigations and conducted contact tracing. Between March 2020-July 2021,
36 636 COVID-19 cases (72% males), including 48 clusters (size range 2-10 cases), were reported.
37 Overall case fatality rate was 1.5%. Of case patients, 82% (523) were Indians, and 18% (113)
38 were Americans. On presentation, 22% (138/625) of cases were asymptomatic. The median time
39 from symptom onset to notification to the Health Unit was three days (Interquartile range 1-5).
40 The Health Unit identified 2,484 contacts (positivity rate 25%). Frequency of case presentation
41 in the US Mission India closely resembled the pattern of COVID-19 waves in India. The attack
42 rates ranged over the time period between 10-19%, the highest at 19% in Delhi.

43 **Conclusions:** COVID-19 mitigation strategies were implemented in collaboration with
44 multiple agencies and helped prevent the transmission of COVID-19 and large COVID-19
45 clusters in the US Mission India.

46 **Key words:** COVID-19, mitigation strategies, contact tracing, US Mission India

47

48

49 **Introduction**

50 Coronaviridae are an RNA family of viruses that have the tendency to jump from animals to
51 humans. ¹ In the past two decades, three human coronaviruses have emerged leading to acute
52 respiratory illness and significant morbidity and mortality: severe acute respiratory syndrome
53 coronavirus (SARS-CoV-1), Middle Eastern respiratory syndrome coronavirus (MERS-CoV),
54 and most recently, COVID-19 coronavirus (SARS-CoV-2). In December 2019, SARS-CoV-2
55 first emerged in Wuhan, China. COVID-19, the disease caused by infection with SARS-CoV-2,
56 was subsequently labeled as a pandemic by WHO in March 2020 due to its rapid rate of spread
57 worldwide and associated mortality and complications³, including rare neurological delayed
58 complications like transient ischemic attacks. ⁴

59 Between March 2020 and June 2021, over 30 million cases of COVID-19 were diagnosed in
60 India, including two major waves in September-December 2020 and April-May 2021.⁵ During
61 that period, over 600 COVID-19 cases occurred in the United States Diplomatic Mission to India
62 (US Embassy and Consulates in India) American employees and their family members, Indian
63 employees, contractors, and household staff. Throughout this period, as part of its COVID-19

64 public health response program, US Mission India implemented COVID-19 mitigation measures
65 and case investigation with contact tracing for all cases. It further offered and administered
66 COVID-19 vaccination to employees upon availability beginning in April 2021.

67 As part of an after-action-review exercise to inform future response efforts, we assessed the
68 COVID-19 response across the five US Mission India posts (New Delhi, Chennai, Kolkata,
69 Mumbai, and Hyderabad) to fill the gap in knowledge about COVID-19 transmission and
70 mitigation in the unique community of US Mission sites in India. In this report, we describe the
71 completeness, timeliness, and effectiveness of COVID-19 mitigation activities. We describe the
72 COVID-19 cases in US Mission, including a comparison to cases in India overall and in specific
73 consular cities between March 2020 and July 2021.

74 **Methods**

75 **Study design:** We drew the data from information collected through non-systematic COVID-
76 19 contact tracing and described the COVID-19 mitigation activities undertaken by US Mission
77 India in 2020 and 2021. This was a secondary analysis of case investigation and contact tracing
78 data collected by the Health Unit from March 2020 – July 2021.

79

80 **Study site:** US Mission India facilities: Embassy New Delhi, Consulate General Mumbai,
81 Consulate General Chennai, Consulate General Hyderabad, and Consulate General Kolkata.

82

83 **COVID-19 mitigation activities:** We collected and compiled information about the US
84 Mission's COVID-19 response and mitigation activities during the study period. This included a
85 review of policy and guidance documents and standard operating procedures; execution of

86 trainings, webinars, COVID-19 group meetings, seminars, town halls, and vaccination drives;
87 and development and dissemination of newsletter articles and management notices.

88

89 **Analysis of health unit case and contact investigation program:** We included
90 eligible participants from Delhi, Mumbai, Hyderabad, Kolkata, and Chennai sites.

91 *Inclusion criteria:* All US direct hires (USDH), eligible family members (EFM), locally
92 employed staff (LES), local guard force (LGF), and others (housekeepers, nannies, and drivers
93 working for Americans and contractors) who either tested positive for COVID-19 by rapid
94 antigen test or Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) / had a clinical
95 diagnosis of COVID-19 while posted or during travel within India, or tested positive/ had a
96 clinical diagnosis of COVID-19 while on a temporary personal or official visit to India during
97 the study period.

98 *Exclusion criteria:* All USDH, EFM, LES, LGF, and others (housekeepers, nannies, and drivers
99 working for Americans and contractors) who tested positive for COVID-19/ had a clinical
100 diagnosis of COVID-19 while they were traveling outside of India for official or personal
101 reasons.

102 A COVID-19 cluster was defined as two or more epidemiologically linked cases during the study
103 period.

104

105 We abstracted the COVID-19 case data for US Mission cities in India (Delhi, Mumbai,
106 Hyderabad, Kolkata, and Chennai Missions) from the Ministry of Health and Family Welfare
107 (Government of India) website for comparison with reported US Mission cases in those
108 respective cities.

109

110 **Data analysis:** We calculated the distribution frequency of selected variables, including
111 nationality, for each of the US Mission in India. Case investigation and contact tracing data
112 included demographic data for both cases and contacts, date of symptom onset, date of contact
113 by the Health Unit case investigation and contact tracing program, number of contacts, duration
114 of isolation and outcome for cases, contact type (i.e., symptomatic or asymptomatic), and test
115 results for contacts. For all COVID-19 cases, descriptive analysis was performed to assess age,
116 sex, frequency of case identification by Mission (epidemic curve), contacts per case, positivity
117 rate among contacts by type of contact (i.e., household, office, or social), and comparison of US
118 Mission case trends with overall case trends in India and Consular cities. We used the Chi-square
119 test to assess the association between selected categorical variables and calculated Odds Ratio
120 (OR) with a 95% Confidence Interval (C.I). The data were analyzed using Epi Info Software,
121 version 7.2.4.1 (US CDC).

122

123 **Ethical considerations:** We have obtained approvals from US CDC (Atlanta) and Bureau of
124 Medical Services (Washington, D.C.), US Department of State, for the secondary data analysis
125 of pre-existing dataset of COVID-19 public health response at US Mission India. This study did
126 not involve any primary data collection; hence consent from participants or parents in case of
127 dependent children was not required. This review was deemed non-research by the Office of the
128 Associate Director for Science of US CDC, hence a full Institutional Review Board approval not
129 recommended. The dataset was obtained after stripping of all personal identifying information in
130 order to maintain the confidentiality of the participants.

131


132 Results

133 US Mission in India reported its first COVID-19 case in March 2020 from New Delhi. Between
134 March 2020 and July 2021, a total of 636 COVID-19 cases (72% males), including 48 clusters,
135 were reported from the US Mission – India (Figure 1). The median age was 42 years, with an
136 interquartile range of 35-49 years. Overall, 82% (523) were Indians, and 18% (113) were
137 Americans.

138

139 **Figure 1. COVID-19 cases and mitigation activities in US Mission, India, Mar 2020-July**
140 **2021 (n=634)**

141



142

143

144

145 **COVID-19 mitigation activities undertaken at US Mission in India**

146 In response to COVID-19, the US Mission in India, in collaboration with internal US Mission
147 divisions, initiated multiple activities, including education sessions for mission staff, hands-on
148 training and demonstration for infection prevention and control, health and safety assessments,
149 and issuing guidelines at regular intervals. In addition, US Mission Health Unit and US Centers
150 for Disease Control and Prevention (CDC) India office initiated a program for COVID-19 case
151 investigation and contact tracing follow-ups. (Figure 1)

152 The education sessions included health education and risk communication through open forum
153 webinars and virtual town halls, which were conducted in both English and Hindi for better
154 outreach. Periodic management notices and newsletter articles were shared with the Mission
155 community, informing them about the sessions. Targeted infection prevention and control (IPC)
156 training sessions included hands-on demonstrations for various sections of the workforce,
157 including supervisors, contract cleaning staff, locally employed staff (LES), motor pool, and
158 cafeteria staff. Other trainings included personal protective equipment training, cleaning and
159 infection training, social distancing training, and hand washing training. Health and safety
160 assessments were done for congregate workplace settings, and recommendations were provided
161 for modified layouts to promote physical distancing, improved ventilation, and air circulation,
162 and cleaning and sterilization guidance.

163 US Mission India Health Unit, CDC, and other agencies collaborated and developed guidelines
164 for COVID-19 to maintain the continuity of the Mission's critical activities. Workplace risk
165 reduction guidelines included guidance on mask use, physical distancing, staying at home when
166 ill, increased telework and virtual meetings, and temperature screening and symptom checking.
167 Other guidance topics included monitoring and evaluating COVID-19 cases and contacts,
168 COVID-19 case cluster identification and response, travel-associated guidance for domestic and

169 international travel, and case isolation and contact quarantine support. Once the COVID-19
170 vaccine became available in April 2021, the Health Unit planned and implemented vaccination
171 drives for all Mission staff and community.

172 Between May 2020 and July 2021, the US Mission collaborated with the COVID-19 working
173 group experts to conduct a weekly "Doctors are In," Webex seminar to address question from the
174 US Mission community. To reduce the risk of COVID transmission in the workplace, the US
175 Embassy Health Unit implemented the strategy of symptom self-screening. All employees were
176 instructed to stay at home and update the Health Unit if they are sick, if anyone in their family
177 (living in the same household) is sick, if they test positive for COVID-19, or if anyone in their
178 family tests positive for COVID-19. Employees required clearance from a medical provider to
179 return back to work. Numerous other mitigation measures were added, including temperature
180 screenings, a mask mandate, installation of hand sanitizers (with foot-operated dispensers)
181 outside every building, and the promotion of telework.

182 The core contact tracing team closely followed COVID-19 guidance in India and around the
183 world to implement Indian guidance (the law of the land) in coordination with US guidance
184 (being a US Mission). Where there was divergence, the US Mission followed the stricter of the
185 two to ensure that both Indian and US guidance was followed. Familiarity with guidance in other
186 countries was also important within this diplomatic community as some essential official travel
187 took place even during the lockdowns.

188 We ensured that all cases and contacts completed government-recommended isolation or
189 quarantine as appropriate, and underwent the recommended COVID-19 testing based on
190 exposure and symptoms onset as per the guidelines.

191

192 **Descriptive analysis of the COVID-19 cases in US Mission in India**

193 Of the reported 636 cases among the US Mission, the case fatality rate was 1.5% (10/636). Of
194 the 10 deaths, eight occurred in 2021, nine were Indian, one was from the Chennai consulate, and
195 nine were from the New Delhi Embassy.

196 The distribution of COVID-19 cases in the US Mission India closely resembled the pattern of
197 COVID-19 cases in India. In 2020, the cases peaked during the first wave from October and
198 November; similarly, the cases peaked in 2021 during the second wave from April-May 2021.
199 COVID-19 case trends from the individual consulates mirrored their respective host city trends
200 (Figure 2). The peak in cases in 2020 came early in Chennai, Hyderabad, and Mumbai from
201 June-August compared to October-November in Delhi and Kolkata. In 2021, cases peaked in
202 Delhi, Chennai, Hyderabad, Kolkata, and Mumbai in April. (Figure 2)

203

204

205

206

207


208

209

210


211 **Figure 2. COVID-19 cases by month in US Mission, India, Mar 2020-July 2021 (n=634)**

212




213

214



215

216



217

218

219

220

221 We identified and responded to 48 COVID-19 clusters across the US Mission in India. The
222 median size of the cluster was 2 cases (range 2-10 cases), and 80% (38) clusters included ≤ 3
223 cases.

224 Comparing the COVID-19 cases among the consulates in 2020, we observed that attack rates
225 among consulates ranged between 3-6%, the highest at 6% in Delhi. The overall attack rate did
226 not differ between Americans (3%) and Indians (5%). However, in the Kolkata consulate,
227 Americans had the highest attack rate of 16% compared to 4% among Indians. (Table 1)

228 In 2021, the attack rates among consulates ranged between 7-14%, the highest at 14% in
229 Hyderabad. The overall attack rate is similar between Americans (10%) and Indians (10%).
230 However, at the Kolkata consulate, Americans had the highest rate of 21% compared to 7%
231 among Indians. Comparing the overall COVID-19 cases amongst consulates between June 2020-
232 July 2021, attack rates ranged between 10-19%, the highest at 19% in Delhi. In the Kolkata
233 consulate, Americans had the highest overall rate of 37% compared to 12% among Indians.
234 However, the overall attack rate across all consulates was similar at 13% among Americans
235 compared to 15% among Indians. (Table 1)

236

237

238

239

240

241

242 **Table 1. COVID-19 Cases and attack rate in US Mission India, Mar 2020-July 2021**

243 **(n=636)**

Year 2020

Consulate	A.R.			A.R.			Total	N	AR %
	American	n	%	Indian	n	%			
Chennai	2	92	2	12	405	3	14	495	3
Delhi	19	536	4	125	1984	6	144	2520	6
Hyderabad	1	86	1	21	320	7	22	406	5
Kolkata	3	19	16	11	249	4	14	268	5
Mumbai	3	145	2	17	563	3	20	708	3
Total	28	878	3	186	3521	5	214	4397	5

Year 2021

Consulate	A.R.			A.R.			Total	N	AR %
	American	n	%	Indian	n	%			
Chennai	7	92	8	29	405	7	36	495	7
Delhi	49	536	9	210	1984	11	259	2520	10
Hyderabad	8	86	9	49	320	15	57	406	14
Kolkata	4	19	21	18	249	7	22	268	8
Mumbai	17	145	12	31	563	6	48	708	7
Total	85	878	10	337	3521	10	422	4397	10

244

Year 2020-21

Consulate	A.R.			A.R.			Total	N	AR %
	American	n	%	Indian	n	%			
Chennai	9	92	10	41	405	10	50	495	10
Delhi	68	536	13	335	1984	17	403	2520	16
Hyderabad	9	86	10	70	320	22	79	406	19
Kolkata	7	19	37	29	249	12	36	268	13
Mumbai	20	145	14	48	563	9	68	708	10

Grand Total 113 878 13 523 3521 15 636 4397 14

245
 246 People between the ages of 41-51 years had the highest caseload, while people above the age of
 247 60 years had the highest case-fatality rate. (Table 2) At the time of presentation at the Med Unit,
 248 about 22% (138/625) of cases were asymptomatic. Among the 498 symptomatic cases, 63%
 249 reported fever, followed by body aches (48%), cough (43%), headache (30%), and sore throat
 250 (30%). (Figure 3)

251
 252 **Table 2. Age group wise cases and mortality rate among COVID-19 cases, US Mission**
 253 **India, March 2020 - July 2021**

254


Age group	Cases	Percent	Mortality	Case fatality rate (%)
1 - <11	9	1	0	0
11 - <21	13	2	0	0
21 - <31	78	12	0	0
31 - <41	176	28	0	0
41 - <51	220	35	3	1.4
51 - <61	121	19	3	2.5
61 - <71	11	2	2	18
81 - <90	1	0	1	100
TOTAL	629	100	9	1.5

255

256

257 **Figure 3. Symptoms at presentation among COVID-19 cases, US Mission India, March**
258 **2020 - July 2021 (n=498)**

259



260

261

262 Among the 627 cases who reported their smoking status, 15% (96/627) were smokers, 5%
263 (34/627) were past smokers, and 10% (62/627) were current smokers. Overall, 27% (167/627)
264 had comorbidities. Among 167 cases with comorbidities, 57% (96/167) reported hypertension,
265 with a 5% (5/96) mortality rate (Table 3). Moreover, 2% (11/627) reported reinfection with
266 COVID-19.

267 The case fatality rate (CFR) was 3.5% (8/230) among those age >45 years compared to 0.5%
268 (2/398) among those < 45 years (Odds Ratio [OR] 7.1, CI:1.5-34, p=0.004). Among cases with
269 both hypertension and diabetes, the CFR was 11% (4/37) compared with 1% (6/391) among
270 those without either comorbidity (OR: 11.9, CI:3.2-44.5, p <0.0005). The fatality rate reported in
271 US Mission India was 2.5 per 1000 population at risk (Tables 1 and 2). (New Delhi was 3.57 per
272 1000 population at risk, and Chennai was 2.01 per 1000 population at risk).

273
274
275
276
277

Table 3. Comorbidity among COVID-19 cases, US Mission India, March 2020 - July 2021 (n=167)

Comorbidity	Number	%	Deaths	%
Hypertension	96	57	5	5
Diabetes	69	41	4	6
Asthma	50	30	1	2
Heart Disease	11	7	1	9
Lung disease	3	2	0	0
Liver disease	1	1	0	0
Hypertension and diabetes	37	22	4	11
Any one comorbidity with age >45 years	99	59	6	6
Any two comorbidities with age >45 years	38	23	5	13
Any three comorbidities with age >45 years	8	5	1	13
Hypertension and diabetes with age >45 years	25	15	4	16
Hypertension, diabetes, and heart disease with age >45 years	2	1	1	50


278
279
280

281 The median time from symptom onset to the notification (in days) to Health Unit in Mission
282 India was three days (Interquartile range 1-5). The median time from symptom onset to COVID-
283 19 testing (n=491) was three days (interquartile range 2-15 days). The most frequently reported

284 reason for the delay in notification to Health Unit in Mission India among cases was the
285 perception of symptoms as fatigue (25%), delay from the local treating physician in suspecting
286 COVID-19 (21%), and perception of initial sign to be a seasonal allergy (17%) or COVID-19
287 vaccine side effect (15%). (Figure 4)

288
289 **Figure 4. Perception among COVID-19 cases for delay in notification COVID-19 cases, at**
290 **US Mission India, March 2020 - July 2021 (n=353)**

291



292

293

294

295

296 Laboratory confirmation of the COVID-19 cases was mostly from RT-PCR (485/489), followed
297 by a rapid antigen test (140/144) at a hospital or a private laboratory. Cycle Threshold Scores
298 (C.T. score) for RT-PCR were available for 273 cases with RT-PCR (median 19 with an
299 interquartile range of 17-21). Eleven cases were diagnosed clinically, and (47%) 21/45 had a

300 chest x-ray for COVID-19. Overall, 8% (51/619) reported travel history within two weeks before
301 the infection; 44 Domestic travel (14 in 2020 and 30 in 2021) and 11 international travel (1 in
302 2020 and 10 in 2021).

303
304 Two third of the cases received Vitamin C, Zinc, and Vitamin D as part of the COVID-19
305 treatment, and half received Ivermectin and Azithromycin. (Figure 5) Hospitalization was 7%
306 (45/627); 44 Indian and 1 American. 6% (20/326) who received Ivermectin as part of COVID-19
307 treatment got hospitalized compared to 8% (25/310) who did not receive Ivermectin showing no
308 statistically significant difference (Odds Ratio 0.7, C.I:0.4-1.37, p 0.8). Indians were following
309 the Government of India's Treatment guidance while Americans followed US guidelines.

310

311

312

313

314

315

316


317

318

319 **Figure 5. Treatment history among COVID-19 cases US Mission India, March 2020 - July**

320 **2021 (n=627)**

321



322

323

324

325

326 All cases were isolated (14 days initially) as per the Ministry of Health and Family Welfare,
327 Government of India guidelines, and contact tracing was done for each reported case. All close
328 contacts were recommended quarantine for 14 days (per Government of India policy), monitored
329 for COVID-19 symptoms, and tested as per the Government of India recommended guidelines
330 on the fifth day following exposure. Of the 636 reported cases, the Health Unit conducted case
331 investigations and found 2,484 contacts between March 2020-July 2021. The overall contact
332 positivity rate was 25% (range 20-26% among all consulates). Office contact positivity rate was
333 highest in Hyderabad (14%), household contact positivity rate highest in Kolkata (70%), social
334 contact positivity rate highest in Delhi (9%), and family contact positivity rate was highest in
335 Mumbai 43%. (Table 4)

336

337 **Table 4. Contact positivity among COVID-19 cases US Mission India, March 2020 - July**
 338 **2021 (n=627)**

339
 340

Consulates	Office			Household			Social			Family			Total		
	n	+ve	%	n	+ve	%	n	+ve	%	n	+ve	%	n	+ve	%
Chennai	29	1	3	4	0	0	0	0	0	100	33	33	133	34	26
Delhi	390	37	9	103	15	15	56	5	9	1173	394	34	1722	451	26
Hyderabad	136	19	14	11	0	0	13	0	0	169	48	28	329	67	20
Kolkata	23	1	4	10	7	70	1	0	0	88	24	27	122	32	26
Mumbai	91	2	2	11	5	45	0	0	0	76	33	43	178	40	22
Overall	669	60	9	139	27	19	70	5	7	1606	532	532	2484	624	25

341
 342

343 Among the 530 who reported their vaccine history till July 2021, 74% had taken Moderna, 10%
 344 Covishield and the rest had other vaccines (Covaxin and Sputnik) available in India. Vaccination
 345 started in India in January 2021 India (initially, only high-risk individuals or those above 60
 346 years were eligible for vaccination). US Mission in India initiated vaccination for all staff in
 347 April 2021.

348

349 Discussion

350

351 COVID-19 mitigation strategies were well planned and implemented in collaboration with
352 multiple agencies in the US Mission India. Although the case investigation and contact tracing
353 program led by the Health Unit New Delhi was labor intensive, it went a long way in preventing
354 the transmission of COVID-19 and large COVID-19 clusters in the US Mission India. Cases
355 peaked during the waves in each city, which was as expected, but the Mission numbers stayed
356 low.

357 One-fifth (20%) of the cases at presentation were asymptomatic in our analysis; in previous
358 analyses, this percentage was found to be anywhere between 13% and 31%.^{6,7,8} One-third of
359 cases had comorbidities. Case fatality remained low in the US Mission in comparison with
360 overall rates in each respective city and India's national average. US Mission India's COVID-19
361 mitigation strategies and the effectiveness of the contact tracing program likely played a role in
362 low case fatality rates.

363 Most deaths reported within the US Mission occurred in the US Embassy New Delhi, but that
364 can be attributed to the large size of the US Embassy in New Delhi compared to the other
365 Consulates in India. The US Mission countrywide and state-wide mortality ratios were lower
366 compared to those for India and the Consulate cities⁹, as well as compared with estimates
367 published elsewhere^{10 11}. These findings were observed despite the fact that the study population
368 included mostly US Mission India staff, who were working and travelling domestically and
369 internationally throughout the majority of the study period.

370 Americans at the Kolkata consulate had a higher risk of contracting COVID-19 compared with
371 Americans at other US mission cities both overall and in respective years of analysis, with
372 double the risk in 2021. One possible explanation for this could be that the small size of the

373 American community in Kolkata compared with the US Embassy in New Delhi (19 vs. 536)
374 offered less opportunity for social distancing.

375 Our analysis shows there are 11 times more chances of mortality amongst individuals aged >45
376 with co-morbidities Hypertension and Diabetes. The presence of chronic conditions such as
377 coronary heart disease, diabetes, and hypertension increases the risk of severe complications of
378 COVID-19 disease ^{12, 13, 14, 15, 16}, with a finding also seen in our analysis. Another point worth
379 noting is the challenges faced at the peak of second COVID-19 wave in New Delhi, including
380 bed crisis and oxygen crisis.¹⁷

381 Our analysis found that one of four contacts became COVID-19 positive. Martinez-Fierro et al.
382 ¹⁸ found that 42% of contacts tested positive in Mexico. Given the high positivity rate among
383 contacts, early detection. and isolation is the key, as often the contacts can be asymptomatic but
384 are transmitting COVID-19 to others.¹⁹

385 Reasons for delayed notification to the Health Unit suggested that individuals whose occupations
386 required physical labor, such as facility workers (electricians, plumbers, construction workers,
387 masons, carpenters, welders) and security guards, often felt they were overworked and ignored
388 fatigue and body aches. Also, physicians often waited for fever to appear before recommending a
389 COVID-19 test, even though the Government of India (Ministry of Health and Family Welfare)
390 did not have fever as an essential criterion for diagnosing COVID-19. Even in our analysis, fever
391 was only present in 63% of the COVID-19 positive patients. The existing literature supports that
392 fever alone is not a specific indicator of COVID-19 infection, with Schneider et al.²⁰ suggesting
393 that body temperature may be an insufficient indicator of COVID-19 infection and Leal et al. ²¹
394 offer fever as an essential component of a trio of symptoms (fever, anosmia, and ageusia) with
395 high specificity for COVID-19 diagnosis.

396 These findings will be helpful to US Mission India and other US Missions globally, the Indian
397 Ministry of Health, and other US and Indian government agencies and organizations involved in
398 protecting and improving public health. The findings from this analysis will help implement and
399 strengthen the existing COVID-19 mitigation activities for current and future pandemic threats in
400 US Mission India. While COVID-19 clinical outcomes in diplomatic missions have been
401 described elsewhere ²², our analysis describes COVID-19 trajectory, outcomes, and mitigation
402 measures, which have not been analyzed amongst any other diplomatic missions. These results
403 can be adapted and contextualized for use in other similar populations/organizations.

404

405 **Limitation:** We performed a secondary analysis on an existing data set primarily collected for
406 non-systematic COVID-19 contact tracing, with the primary purpose of informing clinical care.

407 As such, some variables of interest were missing, including symptom duration and genomic
408 investigation and analysis. This limited our ability to assess the full clinical spectrum and
409 compare circulating variants within the US Mission community to those circulating in the
410 Consular cities.

411

412 **Conclusion and recommendations:** COVID-19 mitigation strategies in US Mission India
413 were implemented in collaboration with multiple agencies and helped prevent the transmission of
414 COVID-19 and large COVID-19 clusters in the US Mission India.

415 We recommended to prioritize vaccination amongst those >45 years and having multiple
416 comorbidities (hypertension, diabetes, and heart disease). These specific populations are at
417 higher risk for severe complications, including death, and may benefit from targeted mitigation
418 strategies.

419 As pandemics change, mitigation guidelines need to be revisited to ensure that they are
420 appropriate and enforceable. Individuals having occupational and physical demands like facility
421 workers (electricians, plumbers, construction workers, masons, carpenters, welders) and security
422 guards should have targeted education with lower identified thresholds for seeking medical care,
423 and providers should have lower thresholds for suspecting COVID-19 in workers in these
424 professions. Future analysis could include long-term follow-ups, which will be more informative
425 in terms of the long-term effects of COVID-19.

426
427 During the Pandemic times, we demonstrated a collaborative effort among clinicians and public
428 health experts to tackle COVID-19 by preventing the disease rather than just treating the disease.
429 Subsequently, clinicians worked as and alongside public health specialists to achieve lower
430 attack and case fatality rates than expected in a unique population. Lessons learned from this
431 pandemic response can be applied to future pandemics.

432

433 **Acknowledgment**

434 We acknowledge and thank all the US Mission India Staff who contributed to COVID-19 control
435 and mitigation response.

436

437 **Disclaimer**

438 The views expressed in this article are authors' own and not necessarily those of the U.S.
439 Government or US Department of State, Bureau of Medical Services or US Centers for Disease
440 Control and Prevention.

441

442 **References**

443

- 444 1. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis.
445 Methods Mol Biol. 2015; 1282, 1-23.
- 446 2. Meo SA, Alhowikan AM, Al-Khlaiwi T, et al. Novel coronavirus 2019-nCoV:
447 prevalence, biological and clinical characteristics comparison with SARS-CoV and
448 MERS-CoV. Eur Rev Med Pharmacol Sci. 2020; 24 (4), 2012-9.
- 449 3. Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Pneumonia of
450 unknown aetiology in Wuhan, China: potential for international spread via commercial
451 air travel. J Travel Med. 2020; 27 (2), taaa008.
- 452 4. Singh J, Robinson S. An interesting case of COVID-19 with transient ischemic attack as
453 a delayed neurological complication. J Family Med Prim Care. 2022 Jun;11(6):3302-
454 3303. doi: 10.4103/jfmprc.jfmprc_1245_21. Epub 2022 Jun 30. PMID: 36119294; PMCID:
455 PMC9480783.
- 456 5. COVID-19 Map. (n.d.). Johns Hopkins Coronavirus Resource Center. Retrieved July 31,
457 2021, from <https://coronavirus.jhu.edu/map.html>
- 458 6. Chen C, Zhu C, Yan D, Liu H, Li D, et al. The epidemiological and radiographical
459 characteristics of asymptomatic infections with the novel coronavirus (COVID-19): A
460 systematic review and meta-analysis. Int J Infect Dis. 2021 Mar;104:458-464. doi:
461 10.1016/j.ijid.2021.01.017. Epub 2021 Jan 12. PMID: 33444755; PMCID: PMC7833455.

- 462 7. He J, Guo Y, Mao R, Zhang J. Proportion of asymptomatic coronavirus disease 2019: A
463 systematic review and meta-analysis. *J Med Virol.* 2021 Feb;93(2):820-830. doi:
464 10.1002/jmv.26326. Epub 2020 Aug 13. PMID: 32691881; PMCID: PMC7404334.
- 465 8. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM,
466 Salanti G, Low N. Occurrence and transmission potential of asymptomatic and
467 presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.
468 *PLoS Med.* 2020 Sep 22;17(9):e1003346. doi: 10.1371/journal.pmed.1003346. PMID:
469 32960881; PMCID: PMC7508369.
- 470 9. Coronavirus in India: Latest Map and Case Count. Coronavirus in India: Latest Map and
471 Case Count. Published July 2021. Accessed October 3, 2022. <https://covid19bharat.org/>
- 472 10. Chinnaswamy S. SARS-CoV-2 infection in India bucks the trend: Trained innate
473 immunity? *Am J Hum Biol.* 2021 Nov;33(6):e23504. doi: 10.1002/ajhb.23504. Epub
474 2020 Sep 23. PMID: 32965717; PMCID: PMC7536963.
- 475 11. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the
476 COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21.
477 *Lancet.* 2022 Apr 16;399(10334):1513-1536. doi: 10.1016/S0140-6736(21)02796-3.
478 Epub 2022 Mar 10. Erratum in: *Lancet.* 2022 Apr 16;399(10334):1468. PMID:
479 35279232; PMCID: PMC8912932.
- 480 12. Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in
481 progress. *Diabetes Res Clin Pract.* 2020 Apr;162:108142. doi:
482 10.1016/j.diabres.2020.108142. Epub 2020 Apr 9. PMID: 32278764; PMCID:
483 PMC7144611.

- 484 13. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou C.Q. , et al; China Medical Treatment Expert
485 Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N
486 Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020
487 Feb 28. PMID: 32109013; PMCID: PMC7092819.
- 488 14. Duffy EY, Cainzos-Achirica M, Michos ED. Primary and Secondary Prevention of
489 Cardiovascular Disease in the Era of the Coronavirus Pandemic. Circulation. 2020 Jun
490 16;141(24):1943-1945. doi: 10.1161/CIRCULATIONAHA.120.047194. Epub 2020 Apr
491 20. PMID: 32310675; PMCID: PMC7294592.
- 492 15. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, et al. Clinical Characteristics of
493 Covid-19 in New York City. N Engl J Med. 2020 Jun 11;382(24):2372-2374. doi:
494 10.1056/NEJMc2010419. Epub 2020 Apr 17. PMID: 32302078; PMCID: PMC7182018.
- 495 16. Dreher M, Kersten A, Bickenbach J, Balfanz P, Hartmann B, et al. The Characteristics of
496 50 Hospitalized COVID-19 Patients With and Without ARDS. Dtsch Arztebl Int. 2020
497 Apr 17;117(16):271-278. doi: 10.3238/arztebl.2020.0271. PMID: 32519944; PMCID:
498 PMC7171478.
- 499 17. Putting an end to India's oxygen crises. (2022, February 3). UN News.
500 <https://news.un.org/en/story/2022/01/1110922>
- 501 18. Martinez-Fierro ML, Ríos-Jasso J, Garza-Veloz I, Reyes-Veyna L, Cerda-Luna RM, et
502 al. The role of close contacts of COVID-19 patients in the SARS-CoV-2 transmission: an
503 emphasis on the percentage of nonevaluated positivity in Mexico. Am J Infect Control.
504 2021 Jan;49(1):15-20. doi: 10.1016/j.ajic.2020.10.002. Epub 2020 Oct 7. PMID:
505 33035601; PMCID: PMC7538376.

- 506 19. Das AK, Chandra K, Dudeja M, Aalam MK. Asymptomatic SARS-COV-2 carriage and
507 sero-positivity in high risk contacts of COVID-19 cases'. *Indian J Med Microbiol.* 2022
508 Apr-Jun;40(2):279-284. doi: 10.1016/j.ijmmb.2021.12.012. Epub 2021 Dec 31. PMID:
509 34980489; PMCID: PMC8719123.
- 510 20. Schneider A, Kirsten H, Lordick F, Lordick F, Lübbert C, von Braun A. Covid-19 in
511 outpatients-Is fever a useful indicator for SARS-CoV-2 infection? *PLoS One.* 2021 Feb
512 3;16(2):e0246312. doi: 10.1371/journal.pone.0246312. Erratum in: *PLoS One.* 2021 May
513 6;16(5):e0251623. PMID: 33534829; PMCID: PMC7857607.
- 514 21. Leal FE, Mendes-Correa MC, Buss LF, Costa SF, Bizario JCS, de Souza SRP, Thomaz
515 O, Tozetto-Mendoza TR, Villas-Boas LS, de Oliveira-da Silva LC, Grespan RMZ,
516 Capuani L, Buccheri R, Domingues H, Alexander N, Mayaud P, Sabino EC. Clinical
517 features and natural history of the first 2073 suspected COVID-19 cases in the Corona
518 São Caetano primary care programme: a prospective cohort study. *BMJ Open.* 2021 Jan
519 12;11(1):e042745. doi: 10.1136/bmjopen-2020-042745. PMID: 33436471; PMCID:
520 PMC7805372.
- 521 22. Harris JR, Owusu D, O'Laughlin K, Cohen AL, Ben Hamida A, et al. SARS-CoV-2
522 Breakthrough Infections among US Embassy Staff Members, Uganda, May-June 2021.
523 *Emerg Infect Dis.* 2022 Jun;28(6):1279-1280. doi: 10.3201/eid2806.220427. Epub 2022
524 Apr 26. PMID: 35470796; PMCID: PMC9155868.
- 525
526
527
528

Figure 1. COVID-19 cases and mitigation activities in US Mission, India, Mar 2020-July 2021 (n=634)






Figure 2. COVID-19 cases by month in US Mission, India, Mar 2020-July 2021 (n=634)



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.24.23294557>; this version posted August 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure 3. Symptoms at presentation among COVID-19 cases, US Mission India, March 2020 - July 2021 (n=498)



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.24.23294557>; this version posted August 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

Figure 4. Perception among COVID-19 cases for delay in notification COVID-19 cases, at US Mission India, March 2020 - July 2021 (n=353)





Figure 5. Treatment history among COVID-19 cases US Mission India, March 2020 - July 2021 (n=627)



medRxiv preprint doi: <https://doi.org/10.1101/2023.08.24.23291557>; this version posted August 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.